Cloning, Expression And Identification Of Non-Collagenous 1 Domain From A2 Chain Of Mouse TypeⅣ Colagen

It has been well documented that the growth and metastasis of malignant tumors depend largely upon the formation of new blood vessels known as angiogenesis. Once a tumor becomes vascularized, the growth of the tumor is rapid. However the tumor mass can be restricted to within a certain limited size, usually smaller than 2-3mm~3 by inhibiting the target of tumor-related angiogenesis, which is called antiangiogenesis-induced dormancy. Obviously, tumor antiangiogenesis therapy or tumor dormancy therapy appears to be promising.Human canstatin, a fragment of α 2 chain of type IV collagen, has been proved to suppress endothelial proliferation in vitro and tumor growth in vivo significantly. A previous study by Kampaus has shown that ED50 of human canstatin is approximately three times less than that of endostatin, suggesting that canstatin may be more potent in tumor dormancy therapy. The purpose of the present study was to evaluate in vivo antiangiogenesis activity and in vitro effects of recombinant mouse canstatin and their fragments on endothelial cell proliferation which may provide a novel angionenesis inhibitor for tumor antiangiogenesis therapy.Methods1. Cloning and sequencing of mouse canstatin, Can-N and Can-C cDNAA total RNA was extracted from the mouse liver using Trizol Reagent. The mouse canstatin, Can-N and Can-C cDNA were obtained from the total RNA by RT-...